214 related articles for article (PubMed ID: 21775845)
1. Effectiveness and acceptability of medical abortion provided through telemedicine.
Grossman D; Grindlay K; Buchacker T; Lane K; Blanchard K
Obstet Gynecol; 2011 Aug; 118(2 Pt 1):296-303. PubMed ID: 21775845
[TBL] [Abstract][Full Text] [Related]
2. Low-dose mifepristone 200 mg and vaginal misoprostol for abortion.
Schaff EA; Eisinger SH; Stadalius LS; Franks P; Gore BZ; Poppema S
Contraception; 1999 Jan; 59(1):1-6. PubMed ID: 10342079
[TBL] [Abstract][Full Text] [Related]
3. First trimester abortion with mifepristone and vaginal misoprostol.
Knudsen UB
Contraception; 2001 May; 63(5):247-50. PubMed ID: 11448463
[TBL] [Abstract][Full Text] [Related]
4. Acceptability and feasibility of medical abortion with mifepristone and misoprostol in Nigeria.
Okonofua F; Shittu O; Shochet T; Diop A; Winikoff B
Int J Gynaecol Obstet; 2014 Apr; 125(1):49-52. PubMed ID: 24507887
[TBL] [Abstract][Full Text] [Related]
5. Two distinct oral routes of misoprostol in mifepristone medical abortion: a randomized controlled trial.
Winikoff B; Dzuba IG; Creinin MD; Crowden WA; Goldberg AB; Gonzales J; Howe M; Moskowitz J; Prine L; Shannon CS
Obstet Gynecol; 2008 Dec; 112(6):1303-1310. PubMed ID: 19037040
[TBL] [Abstract][Full Text] [Related]
6. Acceptability and feasibility of 400 μg buccal misoprostol after 200 mg mifepristone for early medical abortion in Georgia.
Tsereteli T; Chong E; Louie K; Bokhua Z; Winikoff B
Eur J Contracept Reprod Health Care; 2016 Oct; 21(5):367-71. PubMed ID: 27449873
[TBL] [Abstract][Full Text] [Related]
7. Feasibility of a hospital outpatient day procedure for medication abortion at 13-18 weeks gestation: Findings from Nepal
Blum J; Karki C; Tamang A; Shochet T; Shrestha A; Tuladhar H; Karki A; Sharma J; Abbas DF; Dragoman M; Winikoff B
Contraception; 2019 Dec; 100(6):451-456. PubMed ID: 31491379
[TBL] [Abstract][Full Text] [Related]
8. Simplified medical abortion screening: a demonstration project.
Raymond EG; Tan YL; Comendant R; Sagaidac I; Hodorogea S; Grant M; Sanhueza P; Van Pratt E; Gillespie G; Boraas C; Weaver MA; Platais I; Bousieguez M; Winikoff B
Contraception; 2018 Apr; 97(4):292-296. PubMed ID: 29170088
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and acceptability of a mifepristone-misoprostol combined regimen for early induced abortion among women in Mexico City.
Peña M; Dzuba IG; Smith PS; Mendoza LJ; Bousiéguez M; Martínez ML; Polanco RR; Villalón AE; Winikoff B
Int J Gynaecol Obstet; 2014 Oct; 127(1):82-5. PubMed ID: 24957534
[TBL] [Abstract][Full Text] [Related]
10. Factors Associated With Use of an Online Telemedicine Service to Access Self-managed Medical Abortion in the US.
Aiken ARA; Starling JE; Gomperts R
JAMA Netw Open; 2021 May; 4(5):e2111852. PubMed ID: 34019085
[TBL] [Abstract][Full Text] [Related]
11. A randomized controlled trial of different buccal misoprostol doses in mifepristone medical abortion.
Chong E; Tsereteli T; Nguyen NN; Winikoff B
Contraception; 2012 Sep; 86(3):251-6. PubMed ID: 22305917
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous very low dose mifepristone and vaginal misoprostol for medical abortion.
Kapp N; Borgatta L; Ellis SC; Stubblefield P
Contraception; 2006 May; 73(5):525-7. PubMed ID: 16627039
[TBL] [Abstract][Full Text] [Related]
13. Home self-administration of vaginal misoprostol for medical abortion at 50-63 days compared with gestation of below 50 days.
Kopp Kallner H; Fiala C; Stephansson O; Gemzell-Danielsson K
Hum Reprod; 2010 May; 25(5):1153-7. PubMed ID: 20172871
[TBL] [Abstract][Full Text] [Related]
14. Randomized trial of oral versus vaginal misoprostol at one day after mifepristone for early medical abortion.
Schaff EA; Fielding SL; Westhoff C
Contraception; 2001 Aug; 64(2):81-5. PubMed ID: 11704083
[TBL] [Abstract][Full Text] [Related]
15. Regional differences in surgical intervention following medical termination of pregnancy provided by telemedicine.
Gomperts R; Petow SA; Jelinska K; Steen L; Gemzell-Danielsson K; Kleiverda G
Acta Obstet Gynecol Scand; 2012 Feb; 91(2):226-31. PubMed ID: 21950492
[TBL] [Abstract][Full Text] [Related]
16. [The efficacy and acceptability of mifepristone medical abortion with home administration misoprostol provided by private providers linked with the hospital: a prospective study of 433 patients].
Faucher P; Baunot N; Madelenat P
Gynecol Obstet Fertil; 2005 Apr; 33(4):220-7. PubMed ID: 15894206
[TBL] [Abstract][Full Text] [Related]
17. Mifepristone-misoprostol medical abortion: home administration of misoprostol in Guadeloupe.
Guengant JP; Bangou J; Elul B; Ellertson C
Contraception; 1999 Sep; 60(3):167-72. PubMed ID: 10640161
[TBL] [Abstract][Full Text] [Related]
18. Randomized trial of mifepristone and buccal or vaginal misoprostol for abortion through 56 days of last menstrual period.
Middleton T; Schaff E; Fielding SL; Scahill M; Shannon C; Westheimer E; Wilkinson T; Winikoff B
Contraception; 2005 Nov; 72(5):328-32. PubMed ID: 16246656
[TBL] [Abstract][Full Text] [Related]
19. Acceptability and feasibility of outpatient medical abortion with mifepristone and misoprostol up to 70 days gestation in Singapore.
Tan YL; Singh K; Tan KH; Gosavi A; Koh D; Abbas D; Winikoff B
Eur J Obstet Gynecol Reprod Biol; 2018 Oct; 229():144-147. PubMed ID: 30179732
[TBL] [Abstract][Full Text] [Related]
20. Acceptability and feasibility of the use of 400 μg of sublingual misoprostol after mifepristone for medical abortion up to 63 days since the last menstrual period: evidence from Uzbekistan.
Raghavan S; Tsereteli T; Kamilov A; Kurbanbekova D; Yusupov D; Kasimova F; Jymagylova D; Winikoff B
Eur J Contracept Reprod Health Care; 2013 Apr; 18(2):104-11. PubMed ID: 23387475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
